Genelux is positioning Olvi-Vec at the center of its next-generation cancer immunotherapy strategy, targeting patients with inconsistent responses to existing t

Genelux is positioning Olvi-Vec at the center of its next-generation cancer immunotherapy strategy, targeting patients with inconsistent responses to existing treatments. The biotech outlined the approach at BTIG’s 2026 conference as it engages investors.